The effect of betahistine on prevention of olanzapine-induced weight gain in patients with psychotic disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210409050910N2

Enrollment

120

Registered

2022-04-13

Start date

2021-05-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis. Unspecified psychosis not due to a substance or known physiological condition

Interventions

Intervention 1: Intervention group: Routine treatment + betahistine, patients take 5 to 10 mg of olanzapine daily for 73 days and in these 73 days in the intervention group, betahistine 8 mg twice a d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Not all people with psychosis are treated with olanzapine and do not take effective histamine receptors (antihistamines, etc.).

Exclusion criteria

Exclusion criteria: Patients with concomitant metabolic diseases Patients who are obese. Patients taking other weight gain drugs (such as clozapine) at the same time.

Design outcomes

Primary

Measure	Time frame
Weight: The rate of weight gain in control and intervention groups. Timepoint: Start treatment, weeks 4 and 8 and end treatment. Method of measurement: Scales.;Waist circumference: The rate of increase in waist circumference in control and intervention groups. Timepoint: Start treatment, weeks 4 and 8 and end treatment. Method of measurement: Meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Fahimi

Sabzevar University of Medical Sciences

hossein1fahimi@gmail.com+98 51 4465 1300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026